Colorectal Cancer Screening French Organizations for the Follow-up After Colonoscopy (Tempo-colo)

Association pour le Dépistage Organisé des Cancers dans le Rhône

Status: Unknown

Conditions: Colorectal Cancer

Treatments: Behavioral: Tempo Colo

Study type: Interventional

Funder types: Other

Identifiers

NCT03383367

2016-A01710-51

Details and patient eligibility

About

France is one of the European countries where the incidence of colorectal cancer is the highest among cancers for both sexes. Fecal occult blood screening has been implemented since 2008. However, this screening excludes high risk people who have a 10 to 30 % risk of developing a CRC during their lifetime. Colonoscopy follow up of these persons is not organized, and it is up to the attending physician to recall the date of the surveillance colonoscopy. This results in a poor compliance with the recommendations by these people. A postal reminder of the surveillance colonoscopies sent by The French screening organizations to the patients should increase adherence to follow-up recommendations. The colorectal cancer screening organizations will collects from the hepatogastroenterologists (HGE) informations on colonoscopies of people more than 50 years old who live in the Rhone. These informations will allow to send a reminder 3 months before the date recommended by the HGE. Participation rate and timeliness will be assessed, as well as the severity of the lesions found. A medico-economic analysis will also be carried out.

Enrollment: 33,000 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• people aged 50 years or more ;
• at high risk of colorectal cancer ;
• living in Rhône administrative departement or Metropolitan Lyon

Exclusion criteria

• person with chronic inflammatory bowel disease
• colorectal cancer in diagnosis or treatment period

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33,000 participants in 1 patient group

Tempo Colo

Experimental group

Treatment:

Behavioral: Tempo Colo